Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation

被引:76
作者
Adkins, Farrell C. [1 ]
Gonzalez-Angulo, Ana Maria [2 ]
Lei, Xiudong [3 ]
Hernandez-Aya, Leonel F. [2 ]
Mittendorf, Elizabeth A. [1 ]
Litton, Jennifer K. [2 ]
Wagner, Jamie [1 ]
Hunt, Kelly K. [1 ]
Woodward, Wendy A. [4 ]
Meric-Bernstam, Funda [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
关键词
COMPARING TOTAL MASTECTOMY; 20-YEAR FOLLOW-UP; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; PREMENOPAUSAL WOMEN; CONSERVING SURGERY; RADIOTHERAPY; PHENOTYPE; PATTERNS; THERAPY;
D O I
10.1245/s10434-011-1920-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Triple-negative breast cancer (TNBC) is an aggressive subtype shown to have a high risk of locoregional recurrence (LRR). The purpose of this study was to determine the impact of operation type on LRR in TNBC patients. Methods. A total of 1325 patients with TNBC who underwent breast-conserving therapy (BCT) or mastectomy from 1980 to the present were identified. Clinical and pathological factors were compared by the chi-square test. LRR-free survival (LRRFS), distant metastasis-free survival, and overall survival were estimated by the Kaplan-Meier method. Multivariate analysis was performed by the Cox proportional hazard models. Results. BCT was performed in 651 patients (49%) and mastectomy in 674 (51%). The mastectomy group had larger tumors, a higher incidence of lymphovascular invasion, and higher pathologic N stage (all P < 0.001). At 62-month median follow-up, LRR was seen in 170 (26%) in the BCT group and 203 (30%) in the mastectomy group. Five-year LRRFS rates were higher in the BCT group (76% vs. 71%, P = 0.032), as was distant metastasis-free survival (68% vs. 54%, P < 0.0001) and overall survival (74% vs. 63%, P < 0.0001). On multivariate analysis, T stage (hazard ratio [HR] 1.37, P = 0.006), high nuclear grade (HR 1.92, P = 0.002), lymphovascular invasion (HR 1.93, P < 0.0001), close/positive margins (HR 1.89, P < 0.0001), and use of non-anthracycline or taxane-based adjuvant chemotherapy (HR 2.01, P < 0.0001) increased the LRR risk, while age [ 50 years was protective (HR 0.73, P = 0.007). Operation type (mastectomy vs. BCT, HR 1.07, P = 0.55) was not statistically significant. Conclusions. BCT is not associated with increased LRR rates compared to mastectomy. TNBC should not be considered a contraindication for breast conservation.
引用
收藏
页码:3164 / 3173
页数:10
相关论文
共 50 条
  • [31] Stratifying triple-negative breast cancer: which definition(s) to use?
    Adamo, Barbara
    Anders, Carey K.
    [J]. BREAST CANCER RESEARCH, 2011, 13 (02):
  • [32] Breast-Conserving Therapy for Triple-Negative Breast Cancer
    Gangi, Alexandra
    Chung, Alice
    Mirocha, James
    Liou, Douglas Z.
    Leong, Trista
    Giuliano, Armando E.
    [J]. JAMA SURGERY, 2014, 149 (03) : 252 - 258
  • [33] Estrogen Actions in Triple-Negative Breast Cancer
    Treeck, Oliver
    Schueler-Toprak, Susanne
    Ortmann, Olaf
    [J]. CELLS, 2020, 9 (11) : 1 - 15
  • [34] Biological Subtypes of Triple-Negative Breast Cancer
    Hubalek, Michael
    Czech, Theresa
    Mueller, Hannes
    [J]. BREAST CARE, 2017, 12 (01) : 8 - 14
  • [35] Advances in immunotherapy for triple-negative breast cancer
    Liu, Yang
    Hu, Yueting
    Xue, Jinqi
    Li, Jingying
    Yi, Jiang
    Bu, Jiawen
    Zhang, Zhenyong
    Qiu, Peng
    Gu, Xi
    [J]. MOLECULAR CANCER, 2023, 22 (01)
  • [36] Triple-Negative Breast Cancer A Short Review
    Elias, Anthony D.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (06): : 637 - 645
  • [37] Dissecting the Heterogeneity of Triple-Negative Breast Cancer
    Metzger-Filho, Otto
    Tutt, Andrew
    de Azambuja, Evandro
    Saini, Kamal S.
    Viale, Giuseppe
    Loi, Sherene
    Bradbury, Ian
    Bliss, Judith M.
    Azim, Hatem A., Jr.
    Ellis, Paul
    Di Leo, Angelo
    Baselga, Jose
    Sotiriou, Christos
    Piccart-Gebhart, Martine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15) : 1879 - 1887
  • [38] Genomic Profiling in Triple-Negative Breast Cancer
    Liedtke, Cornelia
    Bernemann, Christof
    Kiesel, Ludwig
    Rody, Achim
    [J]. BREAST CARE, 2013, 8 (06) : 408 - 413
  • [39] Practical Approach to Triple-Negative Breast Cancer
    Gadi, Vijayakrishna K.
    Davidson, Nancy E.
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (05) : 293 - +
  • [40] The Proteomic Landscape of Triple-Negative Breast Cancer
    Lawrence, Robert T.
    Perez, Elizabeth M.
    Hernandez, Daniel
    Miller, Chris P.
    Haas, Kelsey M.
    Irie, Hanna Y.
    Lee, Su-In
    Blau, C. Anthony
    Villen, Judit
    [J]. CELL REPORTS, 2015, 11 (04): : 630 - 644